GCB DLBCL presents lesions leading to deregulated cell motility [GNA13 (mutations)], apoptosis [BCL2 (chromosomal translocations)], cell cycle [MYC (chromosomal translocations)], chromatin regulation [EZH2 (mutations)], immune escape TNFRSF14 (mutations or 1p36 deletions), PI3K/AKT signaling [PTEN (10q23 deletions); MIR17HG (13q31 gains or amplifications)], and DNA damage response [ING1 (deletions)]. Here, EZH2 is linked to diffuse large B-cell lymphoma.